Survival Analysis on TCGA-LUAD (test)
0.752C-indexCURE
Evaluation results
| Method | Links | ||||||
|---|---|---|---|---|---|---|---|
| CURE2026.02 | 0.752 | — | 0.164 | — | — | — | |
| PathMoGSample Size (N)=506, Evaluation Protocol=5-fold cross-validation2026.04 | 0.709 | — | — | — | — | 75.7 | |
| PCLSample Size (N)=506, Evaluation Protocol=5-fold cross-validation2026.04 | 0.683 | — | — | — | — | 63 | |
| HDMoEGenomic Modality=true, Pathology Modality=true2026.05 | 0.675 | — | — | — | — | — | |
| MoMEGenomic Modality=true, Pathology Modality=true2026.05 | 0.672 | — | — | — | — | — | |
| CMTAGenomic Modality=true, Pathology Modality=true2026.05 | 0.669 | — | — | — | — | — | |
| LD-CVAEGenomic Modality=true, Pathology Modality=true2026.05 | 0.665 | — | — | — | — | — | |
| CFDLGenomic Modality=true, Pathology Modality=true2026.05 | 0.664 | — | — | — | — | — | |
| MOTCatGenomic Modality=true, Pathology Modality=true2026.05 | 0.661 | — | — | — | — | — | |
| MCATGenomic Modality=true, Pathology Modality=true2026.05 | 0.659 | — | — | — | — | — | |
| CCLGenomic Modality=true, Pathology Modality=true2026.05 | 0.657 | — | — | — | — | — | |
| CAMRSample Size (N)=506, Evaluation Protocol=5-fold cross-validation2026.04 | 0.651 | — | — | — | — | 67.6 | |
| MARBLE2026.02 | 0.6432 | — | — | — | — | — | |
| TransMILGenomic Modality=false, Pathology Modality=true2026.05 | 0.642 | — | — | — | — | — | |
| SNNTransGenomic Modality=true, Pathology Modality=false2026.05 | 0.638 | — | — | — | — | — | |
| AttnMILGenomic Modality=false, Pathology Modality=true2026.05 | 0.62 | — | — | — | — | — | |
| 2DMambaMIL2026.02 | 0.6198 | — | — | — | — | — | |
| CMHEimplementation=Re-implemented2026.02 | 0.616 | 0.136 | 0.198 | 0.034 | — | — | |
| ABMIL2026.02 | 0.6157 | — | — | — | — | — | |
| RSFSample Size (N)=506, Evaluation Protocol=5-fold cross-validation2026.04 | 0.615 | — | — | — | — | 56 | |
| TransMIL2026.02 | 0.6139 | — | — | — | — | — | |
| DSMIL2026.02 | 0.6114 | — | — | — | — | — | |
| SNNGenomic Modality=true, Pathology Modality=false2026.05 | 0.611 | — | — | — | — | — | |
| CoxSample Size (N)=506, Evaluation Protocol=5-fold cross-validation2026.04 | 0.607 | — | — | — | — | 54.7 | |
| PathGSample Size (N)=506, Evaluation Protocol=5-fold cross-validation2026.04 | 0.605 | — | — | — | — | 66 | |
| FGCNSample Size (N)=506, Evaluation Protocol=5-fold cross-validation2026.04 | 0.605 | — | — | — | — | 70.2 | |
| DTFD-MIL2026.02 | 0.602 | — | — | — | — | — | |
| MaxMILGenomic Modality=false, Pathology Modality=true2026.05 | 0.596 | — | — | — | — | — | |
| MambaMIL2026.02 | 0.5952 | — | — | — | — | — | |
| S4-MIL2026.02 | 0.5945 | — | — | — | — | — | |
| CLAM_SBGenomic Modality=false, Pathology Modality=true2026.05 | 0.594 | — | — | — | — | — | |
| SA-DGNet2026.02 | 0.59 | 0.162 | 0.166 | 0.002 | — | — | |
| SRMambaMIL2026.02 | 0.5876 | — | — | — | — | — | |
| CLAM2026.02 | 0.5874 | — | — | — | — | — | |
| HFBSample Size (N)=506, Evaluation Protocol=5-fold cross-validation2026.04 | 0.584 | — | — | — | — | 56.3 | |
| CLAM_MBGenomic Modality=false, Pathology Modality=true2026.05 | 0.582 | — | — | — | — | — | |
| MeanMILGenomic Modality=false, Pathology Modality=true2026.05 | 0.576 | — | — | — | — | — | |
| GraphSSample Size (N)=506, Evaluation Protocol=5-fold cross-validation2026.04 | 0.555 | — | — | — | — | 61.8 | |
| DeepHit2026.02 | 0.539 | 0.213 | 0.264 | 0.1 | — | — | |
| DeepSurv2026.02 | 0.511 | 0.241 | 0.189 | 0.025 | — | — | |
| ABMILModality=WSI2026.03 | — | — | — | — | 0.554 | — | |
| CoxPHModality=Clinical2026.03 | — | — | — | — | 0.551 | — | |
| DIMAFModality=Multimodal2026.03 | — | — | — | — | 0.604 | — | |
| DIMAFxModality=Multimodal2026.03 | — | — | — | — | 0.623 | — | |
| DIMAFxnodisModality=Multimodal2026.03 | — | — | — | — | 0.578 | — | |
| DIMAFxtxModality=Transcriptomics2026.03 | — | — | — | — | 0.495 | — | |
| DIMAFxwsiModality=WSI2026.03 | — | — | — | — | 0.588 | — | |
| MLPModality=Transcriptomics2026.03 | — | — | — | — | 0.496 | — | |
| MMPModality=Multimodal2026.03 | — | — | — | — | 0.604 | — | |
| PANTHERModality=WSI2026.03 | — | — | — | — | 0.586 | — | |
| Pathway MLPModality=Transcriptomics2026.03 | — | — | — | — | 0.494 | — | |
| PIBDModality=Multimodal2026.03 | — | — | — | — | 0.524 | — | |
| SurvPathModality=Multimodal2026.03 | — | — | — | — | 0.535 | — |